← back to search

Robert M. Grant

Campden BRI (United Kingdom) · GB
Area of research
Infectious Diseases · Religious studies
Research interest
Research interests include Biblical Studies and Interpretation, HIV/AIDS Research and Interventions, HIV Research and Treatment, and HIV/AIDS drug development and treatment.
h-index
100
citations
79,788
works
1,042
NIH funding
primary concept
Medicine
email

Recent publications

Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies
Clinical Infectious Diseases 2024cited by 18position: middledoi
Psychedelic-Assisted Internal Family Systems Therapy
Integral Psychedelic Therapy 2023cited by 0position: contributordoi
Characterizing HIV-Preventive, Plasma Tenofovir Concentrations—A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials
Clinical Infectious Diseases 2022cited by 21position: middledoi
Human Enough: A Qualitative Study of Client Experience With Internet-Based Access to Pre-exposure Prophylaxis.
2021cited by 15position: contributordoi
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
The Lancet 2020cited by 418position: middledoi
Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study
Clinical Infectious Diseases 2020cited by 49position: firstdoi
Human Enough: A Qualitative Study of Client Experience With Internet-Based Access to Pre-exposure Prophylaxis (Preprint)
2020cited by 0position: contributordoi
Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function
JAIDS Journal of Acquired Immune Deficiency Syndromes 2019cited by 23position: middledoi
The epidemiology of 5-methoxy- <i>N, N</i> -dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
Journal of Psychopharmacology 2018cited by 137position: middledoi
A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis
AIDS Patient Care and STDs 2018cited by 98position: middledoi
Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine
Clinical Infectious Diseases 2018cited by 75position: lastdoi
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial
HIV Clinical Trials 2018cited by 69position: middledoi
Skating on thin ice: stimulant use and sub‐optimal adherence to <scp>HIV</scp> pre‐exposure prophylaxis
Journal of the International AIDS Society 2018cited by 66position: middledoi
Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study
Clinical Infectious Diseases 2018cited by 56position: firstdoi
Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report
The Lancet HIV 2018cited by 56position: middledoi
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
The Lancet HIV 2017cited by 216position: middledoi
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial
The Lancet HIV 2017cited by 117position: lastdoi
Sex, PrEP, and Stigma: Experiences with HIV Pre-exposure Prophylaxis Among New York City MSM Participating in the HPTN 067/ADAPT Study
AIDS and Behavior 2017cited by 94position: middledoi
Risk, safety and sex among male PrEP users: time for a new understanding
Culture Health & Sexuality 2017cited by 93position: lastdoi
Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis
JAIDS Journal of Acquired Immune Deficiency Syndromes 2017cited by 74position: middledoi
Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States
AIDS and Behavior 2017cited by 60position: middledoi
Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations
AIDS Research and Human Retroviruses 2017cited by 57position: middledoi
Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature
AIDS and Behavior 2016cited by 210position: middledoi
The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices
Journal of the International AIDS Society 2016cited by 155position: lastdoi
Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework
AIDS and Behavior 2016cited by 150position: lastdoi
Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study
The Lancet HIV 2016cited by 76position: lastdoi
Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing
Antimicrobial Agents and Chemotherapy 2016cited by 73position: middledoi
Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension
Clinical Infectious Diseases 2016cited by 58position: lastdoi
The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study
AIDS and Behavior 2016cited by 53position: lastdoi
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services
JAMA Internal Medicine 2015cited by 626position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David V. Glidden · San Francisco General Hospital21 papers (2012–2022)Albert Liu · San Francisco Department of Public Health20 papers (2012–2018)Peter L. Anderson · University of Colorado Anschutz Medical Campus19 papers (2012–2022)Vanessa McMahan · Harvard University18 papers (2012–2019)K. Rivet Amico · University of Michigan18 papers (2012–2018)Kenneth H. Mayer · Whitman-Walker Health16 papers (2012–2020)Susan Buchbinder · University of California System16 papers (2012–2018) · 13 papers (2012–2019)Linda‐Gail Bekker · Desmond Tutu HIV Foundation11 papers (2012–2018)Suwat Chariyalertsak · Changzhi University8 papers (2012–2018)Monica Gandhi · Chan Zuckerberg Initiative (United States)7 papers (2014–2019)Sybil Hosek · University of Illinois Chicago7 papers (2014–2017)Esper G. Kallás · Instituto Butantan6 papers (2012–2015)Megha Mehrotra · Gilead Sciences (United States)6 papers (2014–2019)Valdiléa G. Veloso · University of Colorado Denver6 papers (2012–2016)Patricia Defechereux · Gladstone Institutes5 papers (2015–2020) · 5 papers (2012–2016)Pedro Goicochea · University of California, Berkeley5 papers (2012–2014)Beatriz Grinsztejn · Instituto Nacional de Saúde5 papers (2014–2018)Howard Horng · University of California, San Francisco4 papers (2015–2017)